S. Lurker Nancy's Insider Trades & SAST Disclosures
S. Lurker Nancy's most recent trade in EyePoint Pharmaceuticals Inc was a trade of 20,000 Restricted Stock Units done . Disclosure was reported to the exchange on Feb. 9, 2025.
Add Superstar Alert
Note
This is a custom search result for pattern S. Lurker Nancy.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
|
EyePoint Pharmaceuticals Inc
|
Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2025 | 20,000 | 0 | - | - | Restricted Stock Units | |
|
EyePoint Pharmaceuticals Inc
|
Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2025 | 20,000 | 205,436 (0%) | 0% | 0 | Common Stock | |
|
Collegium Pharmaceutical Inc
|
Nancy S. Lurker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 12,726 | 12,726 (0%) | 0% | 0 | Common Stock | |
|
EyePoint Pharmaceuticals Inc
|
Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 75,134 | 185,436 (0%) | 0% | 0 | Common Stock | |
|
EyePoint Pharmaceuticals Inc
|
Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 75,134 | 75,133 | - | - | Restricted Stock Units | |
|
EyePoint Pharmaceuticals Inc
|
Nancy S. Lurker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
|
EyePoint Pharmaceuticals Inc
|
Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 12,667 | 25,333 | - | - | Restricted Stock Units | |
|
EyePoint Pharmaceuticals Inc
|
Nancy S. Lurker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 12,667 | 110,302 (0%) | 0% | 0 | Common Stock | |
|
EyePoint Pharmaceuticals Inc
|
Nancy S. Lurker | Director | Purchase of securities on an exchange or from another person at price $ 7.88 per share. | 16 Aug 2024 | 3,173 | 97,635 (0%) | 0% | 7.9 | 25,003 | Common Stock |
|
EyePoint Pharmaceuticals Inc
|
Nancy S. Lurker | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Jul 2024 | 56,350 | 169,050 | - | - | Stock Option (Right to Buy) | |
|
EyePoint Pharmaceuticals Inc
|
Nancy S. Lurker | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Jul 2024 | 56,350 | 281,750 | - | - | Stock Option (Right to Buy) | |
|
EyePoint Pharmaceuticals Inc
|
Nancy S. Lurker | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Jul 2024 | 30,000 | 145,000 | - | - | Stock Option (Right to Buy) | |
|
EyePoint Pharmaceuticals Inc
|
Nancy S. Lurker | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Jul 2024 | 30,000 | 95,000 | - | - | Stock Option (Right to Buy) | |
|
EyePoint Pharmaceuticals Inc
|
Nancy S. Lurker | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Jul 2024 | 26,713 | 182,535 | - | - | Stock Option (Right to Buy) | |
|
EyePoint Pharmaceuticals Inc
|
Nancy S. Lurker | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Jul 2024 | 26,713 | 31,165 | - | - | Stock Option (Right to Buy) | |
|
EyePoint Pharmaceuticals Inc
|
Nancy S. Lurker | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Jul 2024 | 16,666 | 16,666 | - | - | Stock Option (Right to Buy) | |
|
EyePoint Pharmaceuticals Inc
|
Nancy S. Lurker | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Jul 2024 | 16,666 | 50,000 | - | - | Stock Option (Right to Buy) | |
|
EyePoint Pharmaceuticals Inc
|
Nancy S. Lurker | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Jul 2024 | 1,558 | 0 | - | - | Stock Option (Right to Buy) | |
|
EyePoint Pharmaceuticals Inc
|
Nancy S. Lurker | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Jul 2024 | 1,558 | 74,800 | - | - | Stock Option (Right to Buy) | |
|
EyePoint Pharmaceuticals Inc
|
Nancy S. Lurker | Director, Executive Vice Chair | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jul 2024 | 11,111 | 94,462 (0%) | 0% | 0 | Common Stock | |
|
EyePoint Pharmaceuticals Inc
|
Nancy S. Lurker | Director, Executive Vice Chair | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jul 2024 | 11,111 | 22,223 | - | - | Restricted Stock Units | |
|
Alkermes plc
|
Nancy S. Lurker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 17,492 | 17,492 | - | - | Non Qualified Stock Option (Right to Buy) | |
|
Alkermes plc
|
Nancy S. Lurker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 8,013 | 8,013 | - | - | Restricted Stock Unit Award | |
|
Alkermes plc
|
Nancy S. Lurker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Apr 2024 | 22,103 | 22,103 | - | - | Non Qualified Stock Option (Right to Buy) | |
|
Alkermes plc
|
Nancy S. Lurker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Apr 2024 | 11,255 | 11,255 | - | - | Restricted Stock Unit Award | |
|
Alkermes plc
|
Nancy S. Lurker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Apr 2024 | 4,833 | 4,833 | - | - | Non Qualified Stock Option (Right to Buy) | |
|
Alkermes plc
|
Nancy S. Lurker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Apr 2024 | 2,323 | 2,323 | - | - | Restricted Stock Unit Award | |
|
EyePoint Pharmaceuticals Inc
|
Nancy S. Lurker | Director, Executive Vice Chair | Gift of securities by or to the insider at price $ 0.00 per share. | 09 Feb 2024 | 74,681 | 126,889 (0%) | 0% | 0 | Common Stock | |
|
EyePoint Pharmaceuticals Inc
|
Nancy S. Lurker | Director, Executive Vice Chair | Gift of securities by or to the insider at price $ 0.00 per share. | 09 Feb 2024 | 74,681 | 83,351 (0%) | 0% | 0 | Common Stock | |
|
EyePoint Pharmaceuticals Inc
|
Lurker Nancy S. | Director, Executive Vice Chair | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 20,000 | 20,000 | - | - | Restricted Stock Units | |
|
EyePoint Pharmaceuticals Inc
|
S. Nancy Lurker | Director, Executive Vice Chair | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 20,000 | 155,441 (0%) | 0% | 0 | Common Stock | |
|
EyePoint Pharmaceuticals Inc
|
Nancy S. Lurker | Director, Executive Vice Chair | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 17,534 | 0 | - | - | Restricted Stock Units | |
|
EyePoint Pharmaceuticals Inc
|
Nancy Lurker S. | Director, Executive Vice Chair | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 17,534 | 172,975 (0%) | 0% | 0 | Common Stock | |
|
EyePoint Pharmaceuticals Inc
|
Lurker S. Nancy | Director, Executive Vice Chair | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.80 per share. | 09 Feb 2024 | 7,962 | 165,013 (0%) | 0% | 28.8 | 229,306 | Common Stock |
|
EyePoint Pharmaceuticals Inc
|
Nancy S. Lurker | Director, Executive Vice Chair | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.80 per share. | 09 Feb 2024 | 6,981 | 158,032 (0%) | 0% | 28.8 | 201,053 | Common Stock |
|
EyePoint Pharmaceuticals Inc
|
Nancy S. Lurker | Director, Executive Vice Chair | Gift of securities by or to the insider at price $ 0.00 per share. | 09 Feb 2024 | 5,000 | 125,000 | - | - | Stock Option (Right to Buy) | |
|
EyePoint Pharmaceuticals Inc
|
Lurker S. Nancy | Director, Executive Vice Chair | Gift of securities by or to the insider at price $ 0.00 per share. | 09 Feb 2024 | 5,000 | 115,000 | - | - | Stock Option (Right to Buy) | |
|
EyePoint Pharmaceuticals Inc
|
Lurker S. Nancy | Director, Executive Vice Chair | Gift of securities by or to the insider at price $ 0.00 per share. | 09 Feb 2024 | 4,452 | 155,822 | - | - | Stock Option (Right to Buy) | |
|
EyePoint Pharmaceuticals Inc
|
Nancy Lurker S. | Director, Executive Vice Chair | Gift of securities by or to the insider at price $ 0.00 per share. | 09 Feb 2024 | 4,452 | 57,878 | - | - | Stock Option (Right to Buy) | |
|
EyePoint Pharmaceuticals Inc
|
S. Lurker Nancy | Director, Executive Vice Chair | Gift of securities by or to the insider at price $ 0.00 per share. | 09 Feb 2024 | 3,116 | 1,558 | - | - | Stock Option (Right to Buy) | |
|
EyePoint Pharmaceuticals Inc
|
Lurker S. Nancy | Director, Executive Vice Chair | Gift of securities by or to the insider at price $ 0.00 per share. | 09 Feb 2024 | 3,116 | 73,242 | - | - | Stock Option (Right to Buy) | |
|
EyePoint Pharmaceuticals Inc
|
S. Lurker Nancy | Director, Executive Vice Chair | Gift of securities by or to the insider at price $ 0.00 per share. | 23 Jan 2024 | 112,700 | 112,700 | - | - | Stock Option (Right to Buy) | |
|
EyePoint Pharmaceuticals Inc
|
S. Lurker Nancy | Director, Executive Vice Chair | Gift of securities by or to the insider at price $ 0.00 per share. | 23 Jan 2024 | 112,700 | 338,100 | - | - | Stock Option (Right to Buy) | |
|
EyePoint Pharmaceuticals Inc
|
Nancy S. Lurker | Director, Executive Vice Chair | Sale of securities on an exchange or to another person at price $ 24.98 per share. | 23 Jan 2024 | 29,956 | 135,441 (0%) | 0% | 25.0 | 748,250 | Common Stock |
|
EyePoint Pharmaceuticals Inc
|
S. Lurker Nancy | Director, Executive Vice Chair | Sale of securities on an exchange or to another person at price $ 24.97 per share. | 23 Jan 2024 | 5,044 | 165,397 (0%) | 0% | 25.0 | 125,950 | Common Stock |
|
EyePoint Pharmaceuticals Inc
|
S. Nancy Lurker | Director, Executive Vice Chair | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 77,000 | 77,000 | - | - | Stock Option (Right to Buy) | |
|
EyePoint Pharmaceuticals Inc
|
Lurker Nancy S. | Director, Executive Vice Chair | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 75,133 | 150,267 | - | - | Restricted Stock Units | |
|
EyePoint Pharmaceuticals Inc
|
Nancy Lurker S. | Director, Executive Vice Chair | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 75,133 | 193,484 (0%) | 0% | 0 | Common Stock | |
|
EyePoint Pharmaceuticals Inc
|
Lurker Nancy S. | Director, Executive Vice Chair | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 38,000 | 38,000 | - | - | Restricted Stock Units | |
|
EyePoint Pharmaceuticals Inc
|
S. Nancy Lurker | Director, Executive Vice Chair | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.40 per share. | 05 Jan 2024 | 23,043 | 170,441 (0%) | 0% | 20.4 | 470,077 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges